Lithium Americas Corp vs Pfizer Inc — how do they compare? Lithium Americas Corp trades at $3.25 (market cap $1.18B), while Pfizer Inc trades at $26.61 (market cap $154.18B). The key difference: Pfizer Inc is far larger — about 130.7× Lithium Americas Corp's market cap, and Pfizer Inc pays a 6.36% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals.
| LAC | PFE | |
|---|---|---|
Market Cap | $1.18B | $154.18B |
Sector | Basic Materials | Health |
52-Week High | $10.05 | $28.56 |
52-Week Low | $2.71 | $23.60 |
Enterprise Value | $1.30B | $205.67B |
Volume | — | 29,869,932 |
Dividend Yield | — | 6.36% |
Signals from Pluang's Aura AI — not financial advice
Lithium Americas (LAC) trades at $3.23, up 6.95% today, but remains in a bearish technical trend with negative profitability metrics. The company reported a net loss of $122.09 million for 2025 and continues to burn cash from operations. Recent news highlights $175 million financing for Thacker Pass construction, providing balance sheet support amid ongoing capital expenditures exceeding $900 million annually.
While analyst consensus leans positive with no sell ratings, significant execution risks persist as LAC navigates peak construction phase. The stock faces headwinds from negative ROE (-11.35%) and cash burn, though strategic positioning in lithium development offers long-term potential if project timelines and funding are successfully managed.
Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.
Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.
Trailing returns across standard periods
Latest headlines on both assets
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →